Bhat’s article ( 1 ) and its accompanying editorial ( 2 ) addressed the screening and/or surveillance strategies for Barrett’s esophagus (BE). We agree that the incidence of Barrett’s adenocarcinoma (BAc) is lower than that previously claimed ( 1 , 3 ). Consistent with data, variable endoscopy/biopsy protocols and inconsistent endoscopist–pathologist interactions substantially affect the assessment and reported prevalence of this disease ( 4 , 5 ).

Unequivocal definitions, educational programs, and audited interdisciplinary teamwork are needed to obtain more reliable information, as demonstrated by our seven-year experience with a multicenter BE registry (the Esofago di Barrett e Rischio di Adenocarcinoma [EBRA] in Northeast Italy) ( 4 , 5 ). This registry, which is restricted to the records of intestinalized-BE patients and excludes patients with cancers that were diagnosed within a year of enrollment, currently includes 841 patients, with a median follow-up of 44.6 months or 3 058 patient-years ( 6 ). The incidence of high-grade dysplasia (HG-D) is 4.9 (95% confidence interval [CI] = 2.7 to 8.1) patients per 1 000 person-years, and the incidence of BAc is 2.3 (95% CI = 0.9 to 4.7) patients per 1 000 person-years. Among patients with low-grade dysplasia, 32.0 (95% CI = 12.7 to 65.3) per 1 000 patient-years will progress to HG-D or BAc.

These prospectively collected data lie between the earlier “enthusiastic” figures and Bhat’s “pessimistic” findings. Interestingly, Bhat’s findings and our own experience with the EBRA consistently demonstrate that the BE planet has so far been only partially explored.

References

1.
Bhat
S
Coleman
HG
Yousef
F
et al
Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study
J Natl Cancer Inst
 
2011
103
(
13
):
1049
1057
2.
Corley
DA.
Understanding cancer incidence in Barrett’s esophagus: light at the end of the tunnel
J Natl Cancer Inst
 
2011
103
(
13
):
994
995
3.
Hvid-Jensen
F
Pedersen
L
Mohr Drewes
A
Toft Sørensen
H
Funch-Jensen
P.
Incidence of adenocarcinoma among patients with Barrett’s esophagus
N Engl J Med
 
2011
365
(
15
):
1375
1383
4.
Caygill
CP
Zaninotto
G
Rugge
M
Participants of international workshop on Barrett’s registries in Europe. Barrett’s registries in Europe: report of an international workshop
Eur J Cancer Prev
 
2008
17
(
5
):
426
429
5.
Rugge
M
Meggio
A
Cataudella
G
et al
Barrett’s esophagus: still much to learn, but “yes, we can!”
Am J Gastroenterol
 
2008
103
(
11
):
2944
2946
6.
Zaninotto
G
Minnei
F
Guirroli
E
et al
The Veneto Region’s Barrett’s esophagus registry: aims, methods, preliminary results
Dig Liver Dis
 
2007
39
(
1
):
18
25